imatinib mesylate
Orphan DrugFDA Approved, EMA Approved
Description
Imatinib is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR. It is used in the treatment of various hematologic malignancies and has shown efficacy in systemic mastocytosis including urticaria pigmentosa. The drug works by blocking abnormal protein signaling in affected cells.
Indications & Therapeutic Use
chronic myeloid leukemia, acute lymphoblastic leukemia, systemic mastocytosis, urticaria pigmentosa, gastrointestinal stromal tumors
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
imatinib mesylate
| Generic Name | imatinib mesylate |
| Brands | 1 brand available |
| Active Ingredient | imatinib mesylate |
| Drug Class | chronic myeloid leukemia |
| Manufacturer | Novartis |
| Dosage Forms | Oral tablet, 100mg, 400mg |
| Medical Code | L01EA01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00001459 |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes